首页> 外文期刊>Clinical and experimental metastasis >Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion
【24h】

Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion

机译:Nidogen 1和Nuclear Protein 1:ETV5转录因子的新靶标参与子宫内膜癌的侵袭

获取原文
获取原文并翻译 | 示例
           

摘要

Endometrial cancer is the most frequent malignancy of the female genital tract in western countries. Our group has previously characterized the upregulation of the transcription factor ETV5 in endometrial cancer with a specific and significant increase in those tumor stages associated with myometrial invasion. We have shown that ETV5 overexpression in Hec1A endometrial cancer cells induces epithelial to mesenchymal transition resulting in the acquisition of migratory and invasive capabilities. In the present work, we have identified Nidogen 1 (NID1) and Nuclear Protein 1 (NUPR1) as direct transcriptional targets of ETV5 in endometrial cancer cells. Inhibition of NID1 and NUPR1 in ETV5 overexpressing cells reduced cell migration and invasion in vitro and reduced tumor growth and dissemination in an orthotopic endometrial cancer model. Importantly, we confirmed a significant increase of NUPR1 and NID1 protein expression in the invasion front of the tumor compared to their paired superficial zone, concomitant to ETV5 overexpression. Altogether, we conclude that NID1 and NUPR1 are novel targets of ETV5 and are actively cooperating with ETV5 at the invasion front of the tumor in the acquisition of an invasive phenotype to jointly drive endometrial cancer invasion.
机译:子宫内膜癌是西方国家女性生殖道最常见的恶性肿瘤。我们的研究小组先前以子宫内膜癌中转录因子ETV5的上调为特征,认为与子宫肌层浸润有关的那些肿瘤分期显着增加。我们已经显示,HTV1A子宫内膜癌细胞中的ETV5过表达诱导上皮向间充质转化,从而导致迁移和侵袭能力的获得。在目前的工作中,我们已经确定Nidogen 1(NID1)和Nuclear Protein 1(NUPR1)是子宫内膜癌细胞中ETV5的直接转录靶标。在原位子宫内膜癌模型中,ETV5过表达细胞中NID1和NUPR1的抑制作用减少了细胞的迁移和侵袭,减少了肿瘤的生长和扩散。重要的是,我们证实,与它们的配对浅表区相比,NUPR1和NID1蛋白表达在肿瘤的侵袭前沿明显增加,并伴有ETV5过表达。总而言之,我们得出的结论是,NID1和NUPR1是ETV5的新型靶标,并且在获得侵袭性表型的过程中与ETV5在肿瘤的侵袭前沿积极合作,共同驱动子宫内膜癌的侵袭。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号